Foot Disorders in X-linked Hypophosphatemia

Status Completed

Clinical Trial Summary

This study aimed to characterize foot pathologies using X-rays and clinical examination and assess related outcome scores in adolescents and adults with X-linked Hypophophatemia

Clinical Trial Description

A single center, cross-sectional analysis of adolescent and adult patients with XLH with and without previous surgical intervention was performed at the Orthopaedic Hospital Speising, Vienna, Austria. Clinical examination, quality of life questionnaires and radiographic data of foot x-rays in standing position were collected. Radiographic evaluation was performed to analyze foot deformity as well as signs of osteoarthritis at the foot. ;

Study Design

Related Conditions & MeSH terms

Familial Hypophosphatemic Rickets
Hypophosphatemia
X-linked Hypophosphatemia

Clinical Trial Details

NCT number	NCT06067932
Study type	Observational [Patient Registry]
Source	Orthopedic Hospital Vienna Speising
Contact
Status	Completed
Phase
Start date	July 1, 2020
Completion date	July 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02915705` - Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)	Phase 3
Recruiting	`NCT03879915` - Dental Implants in Patients With X-linked Hypophosphatemia
Active, not recruiting	`NCT03193476` - Registry for Patients With X-Linked Hypophosphatemia
Completed	`NCT02526160` - Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)	Phase 3
Recruiting	`NCT05181839` - A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
Completed	`NCT04146935` - Examining the Effect of Burosumab on Muscle Function	Phase 4
Completed	`NCT02750618` - Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)	Phase 2
Active, not recruiting	`NCT03745521` - Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
Completed	`NCT03920072` - Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH	Phase 3
Recruiting	`NCT03748966` - Calcitriol Monotherapy for X-Linked Hypophosphatemia	Early Phase 1
Recruiting	`NCT04419363` - Burosumab in Children and Adolescents With X-linked Hypophosphatemia	Phase 4
Completed	`NCT02163577` - Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)	Phase 2
Active, not recruiting	`NCT03651505` - X-linked Hypophosphatemia Disease Monitoring Program
Completed	`NCT04695860` - Anti-FGF23 (Burosumab) in Adult Patients With XLH	Phase 3
Completed	`NCT02312687` - Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)	Phase 2
Completed	`NCT03596554` - X-linked Hypophosphatemia and FGF21
Recruiting	`NCT03820518` - Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia	Phase 4
Completed	`NCT01571596` - An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia	Phase 1/Phase 2
Completed	`NCT04273490` - Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
Completed	`NCT03489993` - FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)